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eperfusion Injury
utting the Genie
ack in the Bottle?*
athaniel Reichek, MD,
ambiz Parcham-Azad, MD
oslyn and Stony Brook, New York
Genie: A supernatural creature which occupies a par-
allel world to that of mankind . . . Possessing free will, . . .
can be either good or evil.
—Wikipedia (1)
n this issue of the Journal, Mewton et al. (2) describe a rare
vent: a negative study with potentially enormous impact.
heir work, using cardiac magnetic resonance, demon-
trates that administration of a single dose of cyclosporine at
he time of percutaneous coronary intervention for ST-
egment elevation myocardial infarction (STEMI), which
revents or reduces reperfusion injury, does not have adverse
onsequences for left ventricular (LV) remodeling in the
ost-infarction period (2). To put this in context requires
onsideration of a long line of basic research and clinical
rustration on the subject of reperfusion injury in myocardial
nfarction.
See page 1200
Contemporary understanding of acute myocardial infarc-
ion is grounded in the classic experimental infarct studies of
ennings et al. (3) starting in the 1970s. By the mid-1970s,
ecognition of the significance of reperfusion injury in
eperfused myocardial infarction had also come into focus in
xperimental work (4). Subsequent work, stimulated initially
y both the advent of intracoronary mechanical and thrombo-
ytic reperfusion and the emergence of intravenous thrombo-
ytic therapy, systematically evaluated multiple potential
echanisms of reperfusion injury and explored potential
pproaches to the prevention or reduction of reperfusion
njury (5–14). These mechanisms now include oxidative
tress, increased intracellular calcium, rapid restoration of
yocardial pH, inflammatory processes, metabolic modu-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ew York. Supported by the St. Francis Hospital Research Foundation.ation, and opening of the mitochondrial permeability
ransition pore (MPTP) (13–27).
Studies in animal models have shown that 50% of infarct
ize may be related to reperfusion injury, and a number of
trategies reduce infarct size in such models (28). Currently,
interrelated approaches are of particular interest: preven-
ion of MPTP opening, ischemic post-conditioning, and
ctivation of the reperfusion injury salvage kinase (RISK)
athway. Ischemia alters the MPTP, whereas calcium over-
oad and excessive production of reactive oxygen species in
he early minutes of reperfusion trigger the opening of the
PTP (29–32). During reperfusion, the open MPTP
llows free entry of proteins into the mitochondria, which
esults in an osmotic load and mitochondrial swelling and
upture as well as ionic gradient disruption across the
itochondrial membrane leading to hydrolysis of adenosine
riphosphate (29,30,33). Ischemic post-conditioning de-
reases infarct size by limiting reperfusion injury through
epetitive interruption of myocardial perfusion during pri-
ary percutaneous coronary intervention (34). The effect is
inked to the activation of protein kinases, which in turn
ediate their cardioprotective actions through the MPTP
35,36). RISKs are protein kinases that prevent lethal
yocardial reperfusion injury. The RISK pathway can be
ctivated through mechanical as well as pharmacologic
gents, including ischemic post-conditioning and pre-
onditioning. Pharmacologic activators include glucagon-
ike peptide, erythropoietin, atorvastatin, and atrial natri-
retic peptide (34,37–39).
However, clinical implementation of strategies to prevent
eperfusion injury has not been very successful to date (28).
hus, guidelines for the management of STEMI remain
ilent on the subject, and a potentially important approach
o reducing morbidity and mortality of myocardial infarc-
ion remains unused.
Cyclosporine is a known blocker of MPTP opening,
hich can reduce infarct size in experimental models
40–43). Cyclosporine inhibits MPTP opening via its
inding to the peptidylprolyl isomerase cyclophilin D lo-
ated in the mitochondrial matrix. Recently, Piot et al. (44)
eported a successful clinical demonstration of the preven-
ion of reperfusion injury in patients, showing a reduction of
he infarct size by roughly 20% (by cardiac magnetic
esonance) to 40% (by troponin curve) with administration
f a single dose of intravenous cyclosporine at the time of
rimary percutaneous coronary intervention for STEMI,
esulting in reductions in LV end-systolic and -diastolic
olumes, in a small randomized trial reported in the New
ngland Journal of Medicine.
However, cyclosporine is not specific for cyclophilin D
nd also binds to cyclophilin A (45–47). This complex
ould have a detrimental effect on post-myocardial infarc-
ion myocardial remodeling because it inhibits calcineurin,
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ypertrophy is, of course, a common result of moderate- to
arge-size myocardial infarctions. The hypertrophic compo-
ent may be, at least initially, considered to be beneficial,
ffsetting the increased workload on the myocardium im-
osed after myocardial infarction (45). Hypertrophy in this
etting is associated with increased intracellular calcium
r enhanced sensitivity to calcium, and the calcium/
almodulin-dependent protein phosphatase calcineurin
eems to be central to translation of elevated intracellular
alcium levels to trophic signals mediating hypertrophy
46). In consequence, development of cardiac hypertrophy
n experimental infarct models is prevented by calcineurin
nhibition, which can result from administration of cyclo-
porine. Experimental studies using high doses of cyclospor-
ne and prolonged treatment after infarction have clearly
emonstrated such effects (47).
Thus, a need existed to determine whether the cyclospor-
ne protocol developed by Piot et al. (44), using only a single
ose of the agent, would also affect post-infarction remod-
ling. In the original study, 58 patients with acute STEMI
ere randomized to receive a single 2.5-mg/kg dose of
ntravenous cyclosporine or placebo, and infarct size was
ssessed using cardiac enzymes and, in 27 patients, using
elayed enhancement cardiac magnetic resonance infarct
maging on day 5. To address the remodeling issue, the
ame group has now imaged patients from the original
ohort (13 controls, 15 treated with cyclosporine) 6 months
fter infarction. The results showed persistent reduction in
nfarct size with persistently reduced LV end-systolic vol-
me and a strong trend toward reduced end-diastolic
olume at 6 months in the cyclosporine group. There was no
ifference between groups in global LV mass or regional
all thickness in remote, noninfarcted myocardium at 6
onths. The authors conclude that cyclosporine can signif-
cantly decrease the infarct size during reperfusion without
ny detrimental effect on myocardial remodeling over 6
onths.
Clearly, these are small pilot studies and larger multi-
enter, randomized clinical trials will be needed to obtain
ore definitive results. In addition, there are other potential
gents for the prevention of MPTP opening, such as
inocycline, that merit evaluation (48). Further, there are
ther strategies for the prevention of reperfusion injury that
erit further exploration (e.g., ischemic post-conditioning
nd RISK activation). Nonetheless, this is an important
dvance and seems to be the first practical step toward
utting the genie of reperfusion injury back in the bottle.
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